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Pathology has evolved significantly in the past 50 years. 
Even I can feel lot of changes in last 10 years of my 
histopathology practice starting from my residency days 
till the present day and things are now developing even at 
a greater pace. It is very difficult to keep up the pace with 
these ever-changing and developing diagnostic 
modalities.  
Light microscopy was the sole examination technique at 
first and pathology was comparatively simple. However, 
with increasing tumor diagnosis and tumor burden across 
the globe, a strong need was felt to strengthen the 
classification systems so that diseases could be put into 
specific categories and hence treated in a more specified 
and accurate manner. This need gave birth to the 
technique of immunohistochemistry, which was based on 
the principle of antigen retrieval and binding of specific 
antibodies designed for a particular antigen. Nowadays 
well-developed histopathology departments use hundreds 
of antibodies in order to diagnose different kinds of 
diseases particularly several kinds of neoplastic diseases 
including benign and malignant tumors. We can very 
confidently classify tumors broadly into categories of 
carcinoma, lymphoma, sarcoma, neuroendocrine tumor, 
melanoma, perivascular epithelioid cell tumor, metastatic 
tumor etc. Each of these broad groups can be further 
classified into specific categories based on histological 
and immunohistochemical features. This has 
revolutionized the treatment options for patients. 
However, every technique has a limitation. After immense 
and colossal research in the field of 
immunohistochemistry, it is now very much known that 
immunohistochemistry has got its own limitations. 
Despite, for example, cytokeratins which are meant to 
stain carcinomas can also be expressed in sarcomas. 
Likewise, melanocytic markers which are known to 
diagnose melanoma can also show positivity in 
perivascular epithelioid cell tumors. CD99 initially 
considered a very specific marker for Ewing’s sarcoma is 
now known to show expression in osteosarcoma (small 
cell variant), lymphoblastic lymphoma and synovial 
sarcoma. CD56 also shows its positivity in a number of 
tumors including carcinomas, lymphomas, and sarcomas. 
Therefore, we cannot overemphasize the fact that a single 
technique is not enough to diagnose a particular disease. 
It is the combination of clinical features, radiological 
features, histological findings and immunohistochemical 
results that is important for an accurate diagnosis.  
Researchers long ago started feeling that even classifying 
tumors based on histology and immunohistochemistry 
was not enough. The reason was the observation that 
patients having same age, gender, type, and stage of 
disease behaved differently. For instance, patients having 
lung adenocarcinoma, breast carcinoma, malignant 
melanoma, colorectal adenocarcinoma, thyroid 
carcinoma, sarcomas, gastrointestinal stromal tumor 
(GIST), ovarian carcinoma, lymphoma behaved very 
much differently even if they belonged to the same group 
of disease and shared similar demographic details and 
same type and stage of the disease. These findings led 
and compelled investigation, exploration, analysis, testing, 
and experimentation of genetics of disease. I can assure 
you that in future genetics will be the part and parcel of 
every field related to diagnostics, especially pathology. 
At this point of time, fluorescence in situ hybridization 
(FISH), PCR, next-generation sequencing (NGS) and 
tissue microarrays are the genetic techniques used in 
combination with histology and immunohistochemistry for 
diagnosing and classifying malignancies. Now it is 
established that malignancies having similar histological 
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and immunohistochemical features and belonging to the 
same group can behave differently on account of their 
different genetic phenotypes. Using this fact, scientists 
are working very hard to develop targeted therapies 
against different types of genetic aberrations e.g. 
identification of many oncogenes and tumor suppressor 
genes.  
NGS has particularly helped a lot in understanding the 
genetics of a large number of diseases and malignancies 
as it has the capability of sequencing and analyzing 
millions of DNA molecules at reduced rates. Some of the 
genetic aberrations are of prognostic and other are of 
therapeutic interest. With the help of NGS, mutations of 
interest are studied for their prognostic and therapeutic 
values and few are selected to develop targeted 
therapies. NGS is not available routinely in Pakistan and 
very rarely used for research purposes at very few 
centers. I would like to give you few examples of the role 
of genetic studies in finding out molecules of treatment 
and prognostic significance. Lung adenocarcinomas can 
look alike histologically but have different genetic 
makeups. Few genes of interest in lung adenocarcinoma 
are EGFR, ALK and ROS1 against which targeted 
therapies have been developed e.g. erlotinib against 
EGFR mutation and crizotinib in ALK and ROS1 mutated 
adenocarcinomas. GIST having KIT and PDGFRA 
mutations can benefit from imatinib or sunitinib therapy 
whereas SDH deficient GISTs do not benefit from this 
therapy and require second line drug regime. Colorectal 
carcinomas having KRAS mutations behave and respond 
to therapy differently than colorectal carcinomas having 
microsatellite instability (MSI). Breast carcinomas which 
are ER and PR positive are given different therapy than 
those which are triple negative for ER, PR and HER-2/neu 
or which are only HER-2/neu positive. These are very few 
basic examples of very common tumors like a drop in the 
ocean. Unfortunately, the discovery of genetic aberrations 
has outpaced the development of targeted therapies.  
PCR technique is cheaper and very much simpler than 
NGS. The particular gene of interest can be tested in 
tumor tissue and treatment can be based on the results. 
Of course, only limited number of genes can be studied 
as compared to NGS in which millions of molecules can 
be assessed. The ability of the molecular department to 
run PCR tests on formalin fixed tumor tissue is a big 
advantage for the pathologists and treating oncologists 
and every effort should be made to acquire this expertise. 
FISH technique is another very useful and very simple 
technique which works on the principle of binding of the 
fluorescent probe to a complementary antigen of interest. 
We use quite a few FISH tests in our department. We use 
HER-2/neu amplification studies in breast carcinomas, 
FISH break apart probes for Ewing’ sarcoma (EWSR1 
gene rearrangement), synovial sarcoma (X;18) and 
alveolar rhabdomyosarcoma (FOXO1 gene 
rearrangement), N-myc and MDM2 amplifications studies 
for neuroblastoma and liposarcoma respectively, break 
apart probe for ALK gene rearrangement in lung 
adenocarcinoma and 1p and 19q co-deletion studies in 
oligodendrogliomas. Some of these results have 
therapeutic and some have prognostic value for the 
patient. 
Every institute can tailor these techniques according to 
their own needs. Pathologists should assess the tumor 
burden and tumor types being diagnosed in their institutes 
and discuss the need to develop different molecular 
techniques with oncologists and molecular biologists. This 
not only helps to diagnose tumors with accuracy but also 
help oncologists to assess prognosis and treatment plan 
of different tumors.  
I think we have entered the era in our lives where 
genetics has gained an utmost importance in diagnostics 
and therapeutics of diseases and nobody can deny the 
importance of genetics. Therefore, in spite of avoiding the 
understanding of genetics, every university and college 
should make genetics a compulsory part of their 
curriculum as it has already been included in the 
curriculum of undergraduate and postgraduate students in 
the developed world so that doctors have the basic 
knowledge of genetic techniques by the time they become 
qualified pathologists. 
 
 
